Specific knockdown of erbB3, but not IGF-1R, inhibits proliferation of the trastuzumab-resistant breast cancer cells associated with cell cycle G1 arrest and significantly promotes lapatinib-mediated growth inhibition and apoptosis. Here, ERBB3 is linked to breast carcinoma.